Trial Profile
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; SX 682 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Syntrix Biosystems
- 04 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Jun 2026.
- 04 Dec 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jun 2025.
- 26 Jan 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.